[Treatment strategy in non-testicular malignant germ cell tumors in children and adolescents--concept of the MAKEI 83 cooperative therapeutic study of the Society for Pediatric Oncology].
In December 1982 the German Society of Pediatric Oncology (GPO) has initiated a cooperative study for non-testicular malignant germ cell tumors with initial vinblastine, bleomycin and cisplatinum chemotherapy depending on stage and histological grading, followed by ifosfamide, cisplatinum and VP 16 chemotherapy. Dysgerminoma patients with advanced disease are also treated with primary chemotherapy including vinblastine, bleomycin and cisplatinum; radiotherapy is limited to current disease. Patients with more differentiated teratomas receive combination chemotherapy with vinblastine, actinomycin D and cyclophosphamide.
D000293:Adolescent; D000367:Age Factors; D001761:Bleomycin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004407:Dysgerminoma / Q000188:drug therapy*; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007223:Infant; D008297:Male; D013724:Teratoma / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use
D001761:Bleomycin; D003609:Dactinomycin; D014747:Vinblastine; D003520:Cyclophosphamide; D002945:Cisplatin; D007069:Ifosfamide
Behandlungsstrategie für nichttestikuläre maligne Keimzelltumoren bei Kindern und Jugendlichen--Konzept der kooperativen Therapiestudie MAKEI 83 der GPO.